[
    [
        {
            "time": "",
            "original_text": "医药研发外包行业：高成长性依旧，CRO龙头净利润率再创新高",
            "features": {
                "keywords": [
                    "医药研发",
                    "外包",
                    "CRO",
                    "净利润率",
                    "创新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药研发外包行业：高成长性依旧，CRO龙头净利润率再创新高",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "群益证券给予泰格医药买进评级：20H2业绩恢复明显，并且在手订单充足，看好公司长远发展",
            "features": {
                "keywords": [
                    "群益证券",
                    "泰格医药",
                    "买进评级",
                    "业绩恢复",
                    "订单充足",
                    "长远发展"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "群益证券给予泰格医药买进评级：20H2业绩恢复明显，并且在手订单充足，看好公司长远发展",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "中航证券给予泰格医药买入评级，2020年报点评：主营业务平稳增长，国际化进程可期",
            "features": {
                "keywords": [
                    "中航证券",
                    "泰格医药",
                    "买入评级",
                    "主营业务",
                    "国际化进程"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中航证券给予泰格医药买入评级，2020年报点评：主营业务平稳增长，国际化进程可期",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "里昂：升泰格医药(03347)目标价38%至188.73港元 评级“买入”",
            "features": {
                "keywords": [
                    "里昂",
                    "泰格医药",
                    "目标价",
                    "买入"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "里昂：升泰格医药(03347)目标价38%至188.73港元 评级“买入”",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "里昂：泰格医药(3347.HK)去年业绩胜预期 升目标价至188.73港元",
            "features": {
                "keywords": [
                    "里昂",
                    "泰格医药",
                    "业绩",
                    "目标价"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "里昂：泰格医药(3347.HK)去年业绩胜预期 升目标价至188.73港元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "东北证券维持泰格医药买入评级：业绩符合预期，业务恢复业绩弹性高，目标价170.9元",
            "features": {
                "keywords": [
                    "东北证券",
                    "泰格医药",
                    "买入评级",
                    "业绩弹性",
                    "目标价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东北证券维持泰格医药买入评级：业绩符合预期，业务恢复业绩弹性高，目标价170.9元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "中泰证券--泰格医药：主业加速恢复，在手订单持续快速增长，全球化布局可期【公司研究】",
            "features": {
                "keywords": [
                    "中泰证券",
                    "泰格医药",
                    "主业",
                    "订单增长",
                    "全球化布局"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券--泰格医药：主业加速恢复，在手订单持续快速增长，全球化布局可期【公司研究】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "创新药企太多 猴不够用 衍新药的猴子竟能“死而复生”？",
            "features": {
                "keywords": [
                    "创新药企",
                    "猴",
                    "死而复生"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "创新药企太多 猴不够用 衍新药的猴子竟能“死而复生”？",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "超57亿元！泰格医药5.2亿元做5只新基金LP，持续布局投资驱动业务增长！",
            "features": {
                "keywords": [
                    "泰格医药",
                    "基金LP",
                    "投资驱动",
                    "业务增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "超57亿元！泰格医药5.2亿元做5只新基金LP，持续布局投资驱动业务增长！",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]